Bone disease in children with homozygous beta-thalassemia
- PMID: 2306556
- DOI: 10.1016/0169-6009(91)90142-m
Bone disease in children with homozygous beta-thalassemia
Abstract
The histological features of thalassemic bone are imperfectly known, and the roles of bone marrow hyperactivity, iron overload or vitamin D deficiency in the pathogenesis of the disease are not clearly identified. In this study we examined iliac crest biopsies from 17 transfusion-dependent children with homozygous beta-thalassemia and severe radiological skeletal thalassemic changes, including widening of medullary spaces and osteoporosis. Rachitic lesions were not observed. Serum ferritin concentrations were increased in all but one subject. Iron deposits were histochemically detected in bone marrow, at the marrow-bone interface, along cement lines and mineralizing perimeters. Minor changes were present in trabecular bone, and osteomalacia was absent. By contrast, cortical bone exhibited severe changes including fissures and focal mineralization defects. Plasma 25-hydroxyvitamin D (25(OH)D) concentrations measured during the winter (December-May, 6.5 +/- 4.9 ng/ml, mean +/- SD, n = 6) and during the summer (June-November, 13.8 +/- 8.4 ng/ml, n = 9) did not differ from those of age-matched children living in the same country. Seven patients had moderate hypocalcemia but no biological signs suggestive of vitamin D deficiency: all had normal alkaline phosphatase activity, normal or slightly elevated plasma phosphate, only two had low plasma 25(OH)D concentrations and two others supranormal values of plasma immunoreactive parathyroid hormone. These results show that iron overload and vitamin D deficiency do not seem to play an important role in the pathogenesis of thalassemic bone disease, which is characterized by cortical lesions probably related to marrow hyperactivity.
Similar articles
-
Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia.J Clin Endocrinol Metab. 1982 Feb;54(2):276-81. doi: 10.1210/jcem-54-2-276. J Clin Endocrinol Metab. 1982. PMID: 7054221
-
Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia.J Clin Endocrinol Metab. 2003 Aug;88(8):3966-72. doi: 10.1210/jc.2002-021548. J Clin Endocrinol Metab. 2003. PMID: 12915694
-
Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.Haematologica. 1995 Sep-Oct;80(5):398-404. Haematologica. 1995. PMID: 8566878
-
Bone Disease in Thalassemia: A Molecular and Clinical Overview.Endocr Rev. 2016 Aug;37(4):320-46. doi: 10.1210/er.2015-1105. Epub 2016 Jun 16. Endocr Rev. 2016. PMID: 27309522 Review.
-
Thalassemia Minor and Major: Current Management.Indian J Pediatr. 2017 Aug;84(8):607-611. doi: 10.1007/s12098-017-2325-1. Epub 2017 Apr 24. Indian J Pediatr. 2017. PMID: 28435994 Review.
Cited by
-
Iron homeostasis in osteoporosis and its clinical implications.Osteoporos Int. 2012 Oct;23(10):2403-8. doi: 10.1007/s00198-012-1982-1. Epub 2012 Apr 14. Osteoporos Int. 2012. PMID: 22525981 Review.
-
Serum or plasma ferritin concentration as an index of iron deficiency and overload.Cochrane Database Syst Rev. 2021 May 24;5(5):CD011817. doi: 10.1002/14651858.CD011817.pub2. Cochrane Database Syst Rev. 2021. PMID: 34028001 Free PMC article.
-
Growth plate injury of the long bones in treated beta-thalassemia.Skeletal Radiol. 1992;21(1):39-44. doi: 10.1007/BF00243093. Skeletal Radiol. 1992. PMID: 1546335
-
Carbonyl iron and iron dextran therapies cause adverse effects on bone health in juveniles with chronic kidney disease.Kidney Int. 2020 Nov;98(5):1210-1224. doi: 10.1016/j.kint.2020.05.043. Epub 2020 Jun 20. Kidney Int. 2020. PMID: 32574618 Free PMC article.
-
Effects of deferoximine on chondrocyte alkaline phosphatase activity: proxidant role of deferoximine in thalassemia.Calcif Tissue Int. 1995 Sep;57(3):229-36. doi: 10.1007/BF00310264. Calcif Tissue Int. 1995. PMID: 8574942
MeSH terms
Substances
LinkOut - more resources
Medical